[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612604":3},{"organization":4,"outcomesModule":7,"designInfo":17,"detailedDescription":23,"studyPopulation":16,"armGroups":24,"interventions":36,"overallOfficials":16,"centralContacts":45,"locations":51,"responsibleParty":64,"collaborators":16,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":16,"eligibilityCriteria":73,"healthyVolunteers":70,"sex":74,"minAge":75,"maxAge":76,"enrollmentInfo":77,"targetDuration":16,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":54,"whyStopped":16,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Tanta University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":16},[9,13],{"measure":10,"description":11,"timeFrame":12},"Prevention of VAP","Diagnosis of VAP using the CDC\u002FNHSN clinical and radiological criteria for neonatal ventilator-associated events. Outcome measured as the percentage (%) of enrolled neonates who develop VAP during NICU stay or up to 28 days of life.","From enrollment until day 28 of life or NICU discharge, whichever occurs first.",{"measure":10,"description":14,"timeFrame":15},"Incidence of ventilator-associated pneumonia during mechanical ventilation.","during NICU stay",null,{"allocation":18,"interventionModel":19,"interventionModelDescription":16,"primaryPurpose":20,"observationalModel":16,"timePerspective":16,"maskingInfo":21},"RANDOMIZED","PARALLEL","PREVENTION",{"masking":22,"maskingDescription":16,"whoMasked":16},"NONE","Randomised controlled trial",[25,31],{"label":26,"type":27,"description":28,"interventionNames":29},"Lactoferrin group","EXPERIMENTAL","Neonates who will receive oral lactoferrin supplementation.",[30],"Dietary Supplement: Lactoferrin in prevention of VAP",{"label":32,"type":6,"description":33,"interventionNames":34},"Control","who Will not receive",[35],"Other: Control",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":16},"DIETARY_SUPPLEMENT","Lactoferrin in prevention of VAP","oral dose separate from feeds \\[at a daily dose of 100mg\u002Fday\\] via orogastric tube from first day of enrollment till time of successful extubation plus standard preventive measures of VAP; these include semi recumbent position, hand washing, suctioning when needed, endotracheal tube with subglottic secretion drainage, using heat and moisture exchanger filter, oral hygiene, changing of tubes only when needed and changing of ventilator circuit every 5 days.",[26],{"type":6,"name":32,"description":43,"armGroupLabels":44,"otherNames":16},"They will receive standard preventive VAP strategies only.",[32],[46],{"name":47,"role":48,"phone":49,"phoneExt":16,"email":50},"Dalia Ayoub","CONTACT","+201066343989","dalia.ayoub@med.tanta.edu.eg",[52],{"facility":53,"status":54,"city":55,"state":16,"zip":16,"country":56,"countryCode":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":16},"Neonatal Intensive Care Unit, Tanta University Children's Hospital","RECRUITING","Tanta","Egypt","EG",{"type":59,"coordinates":60},"Point",[61,62],31.00192,30.78847,{"lat":62,"lon":61},{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":16,"oldOrganization":16},"SPONSOR_INVESTIGATOR","Dalia Mohamed Salah","Lecturer","100612604","role-of-lactoferrin-in-prevention-of-ventilator-associated-pneumonia-in-neonates-100612604",false,"NCT07255742","Role of Lactoferrin in Prevention of Ventilator Associated Pneumonia in Neonates.","Inclusion Criteria:\n\nneonates requiring mechanical ventilation.\n\nGestational age:\n\nExpected need for mechanical ventilation for ≥ (48hours)\n\nExclusion Criteria:\n\nCongenital anomalies of the lung or airway.\n\nMajor congenital heart disease.\n\nProven early-onset sepsis at enrollment.\n\nSevere perinatal asphyxia (e.g., Apgar \\\u003C 3 at 5 minutes or seizures).\n\nKnown contraindication or allergy to lactoferrin.\n\nSevere gastrointestinal pathology (e.g., NEC stage II or higher).\n\nAny condition deemed by the clinical team to interfere with study participation.","ALL","0 Days","90 Days",{"count":78,"type":79},120,"ESTIMATED","INTERVENTIONAL",[82],"NA","The aim of the study is to\n\n1. Evaluate the preventive value of Lactoferrin on VAP among ventilated neonates.\n2. Evaluate the Primary outcome of Lactoferrin on:\n\n   Sepsis, Feeding intolerance, Vomiting, Constipation or diarrhea\n3. Evaluate the effect of Lactoferrin in critically ventilated neonates on:\n\nIncidence of VAP Duration of mechanical ventilation Duration of hospital stay",[85],"Ventilator Associated Pneumonia",[87],"Lactoferrin,VAP","2026-10-02",{"date":90,"type":91},"2026-10-06","ACTUAL",{"date":93,"type":91},"2025-08-01",{"date":95,"type":79},"2026-11-01",{"name":66,"class":6},1]